The Cigna Group (CI) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary reveals mixed signals: strong earnings reaffirmation and optimistic specialty market growth, but concerns about the rebate-free model's impact on margins and growth in 2026. The Q&A section highlights uncertainties in future earnings due to investment spending and restructuring. The lack of specific guidance and potential margin pressures suggest a cautious outlook, balancing positive long-term growth prospects with short-term challenges. The overall sentiment is neutral, reflecting stable but uncertain near-term performance.
Key Financial Performance
Revenue $69.7 billion, with no specific year-over-year change mentioned. The revenue reflects strong business performance and operational execution.
Adjusted Earnings Per Share (EPS) $7.83 per share for the third quarter. The full-year 2025 EPS outlook is reaffirmed at at least $29.60. No specific year-over-year change mentioned.
Evernorth Health Services Revenue $60.4 billion for the third quarter, with Specialty & Care Services revenue up 10% to $26.3 billion. This growth is attributed to strong specialty volume growth and increased biosimilar adoption.
Evernorth Health Services Pretax Adjusted Earnings $1.9 billion for the third quarter, with Specialty & Care Services pretax adjusted earnings up 11% to $928 million. Growth is driven by specialty volume growth and biosimilar adoption.
Pharmacy Benefit Services Revenue $34.1 billion for the third quarter. No specific year-over-year change mentioned.
Pharmacy Benefit Services Pretax Adjusted Earnings $1 billion for the third quarter. No specific year-over-year change mentioned.
Cigna Healthcare Revenue $10.9 billion for the third quarter. No specific year-over-year change mentioned.
Cigna Healthcare Pretax Adjusted Earnings $1 billion for the third quarter. No specific year-over-year change mentioned.
Medical Care Ratio (MCR) 84.8% for the third quarter, driven by an updated view of risk adjustment in the individual exchange business. The full-year MCR is expected to be at the high end of the guidance range of 83.2% to 84.2%.
Operating Cash Flow $3.4 billion for the third quarter. No specific year-over-year change mentioned.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New rebate-free model for pharmacy benefits: Introduced a transformative model designed to improve healthcare affordability and experience for millions of Americans. This model will replace the complex post-purchase rebate process with a simple upfront discount, reducing brand name drug prescription costs by an average of 30%.
Fertility treatments: Evernorth Fertility Pharmacies partnered with EMD Serono to make fertility treatments more accessible and affordable for Americans.
Investment in Shields Health Solutions: Completed a strategic investment in Shields Health Solutions to expand specialty capabilities in the provider-administered specialty market, which represents 40% of the specialty space.
Client renewals and extensions: Secured long-term renewals and extensions with major clients, including the U.S. Department of Defense, Prime Therapeutics, and Centene, ensuring partnerships through the end of the decade.
Specialty & Care Services growth: Delivered 11% adjusted earnings growth in Specialty & Care Services, driven by strong specialty volume growth and biosimilar adoption.
Pharmacy Benefit Services investments: Invested in technology improvements, process reengineering, and data analytics to support new pharmacy benefit models and client recontracting efforts.
Rebate-free pharmacy benefits model: Transitioning to a rebate-free model by 2028, with 50% of the business expected to adopt this model by the end of 2028. This includes upfront discounts and simplified pricing for consumers.
Support for independent pharmacists: Committed to fair pricing reimbursements for independent pharmacists, particularly in rural and at-risk communities.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Drug Pricing and Affordability: Brand name drug prices continue to rise significantly, with some medications costing up to $390,000 per treatment course. This creates affordability challenges for consumers and impacts the company's ability to manage costs effectively.
Regulatory and Legislative Changes: The company faces potential risks from regulatory and legislative changes, including initiatives aimed at lowering brand name drug costs and aligning U.S. prices with other developed countries. These changes could impact revenue and operational strategies.
Pharmacy Benefit Services Margin Pressure: The transition to a rebate-free pharmacy benefits model and renegotiated contracts with large clients are expected to create margin pressure in the Pharmacy Benefit Services segment over the next two years.
Economic Terms for Government Programs: Improved economic terms for contracts with government program partners, such as Centene and the Department of Defense, may lead to reduced profitability in the short term.
Medical Cost Trends: Persistently elevated medical costs, particularly in the individual exchange business, could impact the company's financial performance and medical care ratio.
Investment and Transition Costs: Significant investments in technology, process reengineering, and data analytics to support new models and client renewals will incur short-term costs, potentially impacting profitability.
Debt Levels: The company's debt-to-capitalization ratio increased to 44.9% due to recent investments, which may pose financial risks if not managed effectively.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: The company expects continued strong growth in Cigna Healthcare and Specialty & Care Services, both at the higher end of their respective long-term growth targets for 2026. Evernorth's operating income is expected to be slightly down in 2026 due to investments and contract renewals.
Margin Projections: The Pharmacy Benefit Services segment is expected to experience margin pressure over the next two years due to investments in new models and improved economic terms for long-term strategic clients. However, the company expects margin expansion in the Stop Loss business in 2026.
Capital Expenditures: Significant investments are planned over the next two years to support client renewals, technology improvements, process reengineering, and data and analytical capabilities.
Market Trends: The company is proactively transforming its pharmacy benefits model to meet market demands, including a new rebate-free model to improve affordability and experiences for customers and patients. This model will be fully adopted for Cigna Healthcare's fully insured lives by 2027 and broadly by 2028.
Business Segment Performance: Specialty & Care Services is expected to grow income towards the higher end of its long-term growth target, driven by strong specialty volume growth and increased biosimilar adoption. Pharmacy Benefit Services will see a decline in operating income in 2026 due to investments and contract renewals. Cigna Healthcare is expected to grow operating income towards the higher end of its long-term growth target in 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Anticipated 2025 dividends: The company mentioned that their financial outlook for 2025 includes the potential impact of anticipated 2025 dividends.
Future share repurchases: The financial outlook for 2025 also includes the potential impact of future share repurchases.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the new rebate-free model introduced by Express Scripts?
A:The new rebate-free model is fee-based, delinked, transparent, and ensures the lowest available price for consumers at the counter. It aligns with regulatory priorities and eliminates rebates and linked reimbursements. The model is designed to future-proof the business and address market needs.
Q:What are the expected impacts of the new rebate-free model on Evernorth's growth?
A:Evernorth will not be on its long-term growth algorithm in 2026 due to significant investments in the new rebate-free model and proactive actions around renewals and contract extensions. However, Specialty & Care will grow at the high end of its algorithm, and the new model is expected to strengthen the long-term durability of the pharmacy benefit services business.
Q:What are the three categories to consider when modeling the future of the Pharmacy Benefit Services business?
A:1. The three large clients (Prime Therapeutics, Centene, and DoD) represent roughly $90 billion of annual revenue, with a new margin profile running through the end of the decade. 2. Transitional and investment spending for the rebate-free model will cause margin pressure in 2026 and 2027 but will dissipate thereafter. 3. The fundamental earnings profile of the remaining pharmacy benefit services book is expected to remain comparable to current levels.
Q:What are the benefits of the new rebate-free model for stakeholders?
A:For patients, it ensures the lowest out-of-pocket price and applies out-of-pocket payments to deductibles. Independent pharmacists will receive reimbursement based on drug procurement costs and a dynamic dispensing fee. Employers will benefit from a simple, fee-based payment structure, greater budget certainty, and improved employee satisfaction. Shareholders will gain more visibility, transparency, and predictability of performance.
Q:What is the expected magnitude of the 2026 decline in the Pharmacy Benefit Services business?
A:The decline is attributed to two headwinds: proactive renewals and extensions of large clients, which account for more than half of the decline, and investment and transitional costs for the rebate-free model, which account for less than half. The overall Evernorth segment income is expected to decline slightly from the 2025 level.
Q:What is the expected EPS growth for 2026, and what factors contribute to it?
A:While specific EPS guidance for 2026 was not provided, the growth is expected to be driven by Cigna Healthcare and Specialty & Care growing at the higher end of their algorithms, offset by the decline in the Pharmacy Benefit Services business. Capital deployment and share repurchase strategies will also play a role.
Q:How does the new rebate-free model address employer concerns about rebates?
A:The model eliminates rebates and ensures the lowest available price at the counter. It offers a simple, fee-based payment structure and provides flexibility for employers who may want to transition over a multiyear period. The model is designed to align with market trends and employer needs.
Q:What is the profitability outlook for large contracts in the Pharmacy Benefit Services business?
A:Large contracts typically have lower earnings profiles than the overall portfolio. The company proactively extended and restructured these contracts, which are strategically important. While they run at a lower margin, they are not expected to operate at a loss.
Q:What is the company's approach to public-private partnerships and regulatory engagement?
A:The company emphasizes sustained public-private partnerships and innovation. Examples include transforming prior authorizations, developing fertility solutions, and leading the industry with programs like Encircle for GLP-1s. The company engages in nonpartisan, fact-based, patient-centric collaboration with regulators and policymakers.
Q:What are the key building blocks for Cigna Healthcare's growth in 2026?
A:Key drivers include the repricing of the stop-loss business, which is tracking well toward margin recovery, and growth in the Select segment. The Individual exchange business is expected to decline in membership, but overall, Cigna Healthcare income is expected to grow at the higher end of its long-term algorithm.
Q:What is the long-term margin profile for the Pharmacy Benefit Services business?
A:The long-term margin profile is expected to be around 4%, consistent with previous guidance. The new rebate-free model is expected to provide earnings contributions comparable to current solutions, with portfolio-level margins varying based on client mix.
Q:Review of Unclear Management Responses
A:Management avoided providing specific numerical guidance for the magnitude of the 2026 decline in the Pharmacy Benefit Services business, the exact investment spending levels for 2027, and the EPS growth rate for 2026. Responses were directional and lacked precise details, particularly around profitability and investment spending.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Cigna Group
Department Defense
EMD Serono
HUMIRA
Health Solutions
Healthcare Health
Serono fertility
Shields Health
Therapeutics Centene
Today
administration
affordability experience
benefit model
benefit plan
brand name
commitment customer
consumer
contract benefit
effort
end decade
end term
extension Department
fertility treatment
government program
health care
income end
investment Shields
market investment
model pharmacy
name drug
name medication
partner government
rebate
renewal extension
tailwind headwind
CI Transcript
The Cigna Group (CI) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-13
The Cigna Group (CI) Q1 2026 Earnings Call Transcript
Positive4-30
The earnings call summary indicates strong financial performance, with a 5% increase in adjusted income and 7% growth in adjusted revenues. The improvement in the Medical Care Ratio (MCR) also reflects effective cost management. Additionally, significant share repurchases demonstrate a commitment to shareholder returns. Despite the absence of operational updates and strategic initiatives, the solid financial results and shareholder-friendly actions suggest a positive sentiment. However, the lack of additional insights from the Q&A session slightly tempers the overall outlook, leading to a 'Positive' rating.
The Cigna Group (CI) Q4 2025 Earnings Call Transcript
Positive2-5
The earnings call reveals strong financial performance, exceeding revenue expectations and maintaining robust cash flow. Shareholder returns are significant, and strategic investments are in place. The Q&A section indicates alignment with regulatory expectations and optimistic growth in specialty services. While there are concerns about margin pressures and cash flow conversion, the overall sentiment remains positive due to strong fundamentals and strategic alignment. The positive outlook for the specialty business and shareholder returns further support a positive stock price reaction.
The Cigna Group (CI) Presents at UBS Global Healthcare Conference 2025 Transcript
Neutral11-12
CI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
